Lipoamide channel-binding sulfonamides selectively inhibit mycobacterial lipoamide dehydrogenase. Academic Article uri icon



  • Tuberculosis remains a global health emergency that calls for treatment regimens directed at new targets. Here we explored lipoamide dehydrogenase (Lpd), a metabolic and detoxifying enzyme in Mycobacterium tuberculosis (Mtb) whose deletion drastically impairs Mtb's ability to establish infection in the mouse. Upon screening more than 1.6 million compounds, we identified N-methylpyridine 3-sulfonamides as potent and species-selective inhibitors of Mtb Lpd affording >1000-fold selectivity versus the human homologue. The sulfonamides demonstrated low nanomolar affinity and bound at the lipoamide channel in an Lpd-inhibitor cocrystal. Their selectivity could be attributed, at least partially, to hydrogen bonding of the sulfonamide amide oxygen with the species variant Arg93 in the lipoamide channel. Although potent and selective, the sulfonamides did not enter mycobacteria, as determined by their inability to accumulate in Mtb to effective levels or to produce changes in intracellular metabolites. This work demonstrates that high potency and selectivity can be achieved at the lipoamide-binding site of Mtb Lpd, a site different from the NAD⁺/NADH pocket targeted by previously reported species-selective triazaspirodimethoxybenzoyl inhibitors.

publication date

  • November 26, 2013



  • Antitubercular Agents
  • Bacterial Proteins
  • Dihydrolipoamide Dehydrogenase
  • Enzyme Inhibitors
  • Mycobacterium tuberculosis
  • Sulfonamides
  • Thioctic Acid


PubMed Central ID

  • PMC3894633

Scopus Document Identifier

  • 84895778643

Digital Object Identifier (DOI)

  • 10.1021/bi401077f

PubMed ID

  • 24251446

Additional Document Info


  • 52


  • 51